Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic Acid Combined With Anti-EGFR Rechallenge in mCRC
NCT06714357Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of valproic acid in colorectal cancer (CRC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression Free Survival rate at 16 weeks. Started Mar 2025; status: recruiting.
02
Drugs
valproic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06714357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714357.